Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages by Tracey, L et al.
The University of Notre Dame Australia
ResearchOnline@ND
Medical Papers and Journal Articles School of Medicine
2015
Adverse events following influenza immunization reported by healthcare personnel
using active surveillance based on text messages
L Tracey
A Regan
D Mak
The University of Notre Dame Australia, donna.mak@nd.edu.au
P Effler
Follow this and additional works at: https://researchonline.nd.edu.au/med_article
Part of the Medicine and Health Sciences Commons
This article was originally published as:
Tracey, L., Regan, A., Mak, D., & Effler, P. (2015). Adverse events following influenza immunization reported by healthcare personnel
using active surveillance based on text messages. Infection Control and Hospital Epidemiology, 36 (5), 608-610.
Original article available here:
https://doi.org/10.1017/ice.2015.16
This article is posted on ResearchOnline@ND at
https://researchonline.nd.edu.au/med_article/817. For more information,
please contact researchonline@nd.edu.au.
This is the author’s version of an article published in Infection Control and Hospital 
Epidemiology, May 2015, available online at https://doi.org/10.1017/ice.2015.16 
Tracey,L., Regan, A., Mak, D., and Effler, P. (2015) Adverse events following influenza 
immunization reported by healthcare personnel using active surveillance based on text 
messages. Infection Control and Hospital Epidemiology, 36(5), 608-610.  
doi: 10.1017/ice.2015.16 
Infection Control and Hospital Epidemiology
 
Adverse events following influenza immunisation reported by healthcare presonnel
using SMS-based active surveillance
--Manuscript Draft--
 
Manuscript Number: 34951R1
Full Title: Adverse events following influenza immunisation reported by healthcare presonnel
using SMS-based active surveillance
Short Title: Adverse events following immunisation in HCP
Article Type: Research Brief
Corresponding Author: Lauren E Tracey, MPH
Western Australian Department of Health
Shenton Park, WA AUSTRALIA
Corresponding Author Secondary
Information:
Corresponding Author's Institution: Western Australian Department of Health
Corresponding Author's Secondary
Institution:
First Author: Lauren E Tracey, MPH
First Author Secondary Information:
Order of Authors: Lauren E Tracey, MPH
Annette K Regan, MPH
Donna B Mak, MPH
Paul V Effler, MD
Order of Authors Secondary Information:
Abstract: Studies have demonstrated that healthcare personnel (HCP) have concerns about the
potential side effects of trivalent inactivate influenza vaccine (IIV3).1-3 A recent meta-
analysis of reasons HCP refuse IIV3 indicates the strongest predictors of vaccine
acceptance are belief that the vaccine is safe and belief the vaccine does not cause
the disease it is meant to prevent.1
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1 
 
Adverse events following influenza immunisation reported by healthcare 
personnel using SMS-based active surveillance 
 
Tracey L, MPHa Regan AK, MPHa,b Mak, DB, MPHa,c, Effler PV, MDa,b 
 
a Communicable Disease Control Directorate, Western Australian Department 
of Health, Perth, Western Australia, Australia 
b School of Pathology and Laboratory Medicine, University of Western 
Australia, Perth, Western Australia, Australia 
c School of Medicine, University of Notre Dame, Fremantle, Western Australia, 
Australia 
 
SHORT TITLE: Adverse events following immunisation in HCP 
 
 
 
 
 
 
Contact details: Lauren Tracey, Epidemiologist, Communicable Disease Control 
Directorate, Western Australian Department of Health; Mailing: 227 Stubbs Terrace, 
Shenton Park, Western Australia, 6008, Australia; Phone: +61 89388 4876, Email: 
Lauren.Tracey@health.wa.gov.au  
 
Word count: 903 
Manuscript
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
Introduction 
Studies have demonstrated that healthcare personnel (HCP) have concerns about 
the potential side effects of trivalent inactivate influenza vaccine (IIV3).1-3 A recent 
meta-analysis of reasons HCP refuse IIV3 indicates the strongest predictors of 
vaccine acceptance are belief that the vaccine is safe and belief the vaccine does 
not cause the disease it is meant to prevent.1 
 
Timely vaccine safety information for each new seasonal IIV3 vaccine can be used 
to reassure HCP. In addition, the ability to provide real-time safety profiling of new 
vaccines should form part of emergency preparedness planning, for example in the 
case of rapid development and rollout of vaccines in a pandemic. 
 
Despite ready access to vaccines and concerted efforts to promote uptake, influenza 
vaccination coverage among HCP in Australia has historically been low, ranging 
from 18-66%.5 In a review of 32 studies from the United States (13), Canada (5), 
Europe (11) and others (3), Hofmann et al. found influenza vaccine coverage of less 
than 50% in HCP in the majority (26/32, 81%) of these studies.6 
 
In 2014, the Western Australian Department of Health (“WA Health”) developed the 
Follow-up and Active Surveillance of Trivalent Influenza Vaccine in HCP 
(FASTHealth) program.  FASTHealth is an SMS-based, active influenza vaccine 
safety monitoring program intended to be implemented at the start of each season’s 
annual HCP vaccination program.  
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Methods 
WA Health provides free IIV3 for staff working in government health facilities and 
maintains a centralised record keeping system for recording HCP influenza 
immunisation. In 2014, HCP were asked at the time of vaccination to participate in 
the FASTHealth program to monitor adverse events following immunisation (AEFIs). 
HCP who consented and provided a mobile phone number were sent a text 
message (or ‘SMS’) seven days after vaccination querying whether they had 
experienced any ‘reaction, fever or illness’ following vaccination.   
 
A second SMS was sent 24 hours later to anyone who did not reply to the first 
message. HCP who responded “Yes” to either message were sent a link to a mobile 
phone survey to record the details of their AEFI. Those who opted not to complete 
the smart phone survey and those who did not reply to either SMS were telephoned 
to ascertain specifics of any AEFI via a standardised interview with a research nurse.  
Both surveys were identical in content and asked whether the participant 
experienced fever, headache, fatigue, vomiting, rash, rigors, convulsions or swelling 
or pain at the injection site. Other reported potential side-effects were recorded 
verbatim/as written.  
 
Results  
Between 19 March and 20 May 2014, 1,624 HCP, including medical, administration 
and support staff, were sent an SMS soliciting whether they experienced an AEFI. 
The majority were female (81%) and between 18-44 years of age (56%); 835 HCP 
received intradermal IIV3 (Intanza®: 51.4%) and 789 received an intramuscular IIV3 
(Vaxigrip®: 48.3%; Fluvax®: 0.3%). 
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Of those who were sent an SMS message, 1,432 (88%) replied.  A total of 239 
(17%) of the respondents replied affirmatively that they had experienced one or more 
reactions to the vaccine.  Of those reporting reactions, 184 (77%) provided details 
regarding the AEFI: 66 via the mobile phone survey and 118 by telephone. The 
remaining 55 HCP were lost to follow-up.  
 
Among the 192 HCP who did not reply to the SMS, 65 (34%) were subsequently 
reached by telephone and 20 (31%) of these reported an event. In aggregate, 1,442 
HCP provided complete information regarding the occurrence of AEFI, of which 204 
(14.1% [95% CI 12.2-16.1%]) reported at least one reaction (Figure).  
 
Figure. Responses to the FASTHealth program 19 March – 20 May 2014. 
 
No severe adverse events were reported. A total of 137 HCP reported at least one 
systemic symptom, most commonly fatigue (3.8% [95% CI 2.8-4.8%]), headache 
(3.7% [95% CI 2.7-4.7%]) or respiratory symptoms (3.7% [95% CI 2.7-4.7%]). 115 
HCP reported redness, pain or swelling at the injection site (8.0% [95% CI 6.5-
1.7%]). These results were in keeping with the documented safety profile of IIV3 
vaccine. 
 
Discussion 
Use of SMS technology in the FASTHealth program allowed rapid, active 
surveillance of the safety of IIV3 offered free to HCP as part of the annual influenza 
program. Consistent with previous vaccine safety investigations of seasonal IIV3 in 
HCP, the proportion reporting a potential side-effect was low.4,7 
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As the antigenic components of the influenza vaccine can change season-to-season 
and safety profiles from previous seasons’ formulations may not be applicable to 
current vaccines, it is particularly important to monitor the safety of IIV3 each year.  
Our findings demonstrate the feasibility of implementing a timely, resource-
conserving, vaccine safety monitoring system among HCP each year during 
influenza vaccination season.   
 
Previous methods to capture AEFI following IIV3 in HCP mainly include self-report 
paper questionnaires, which require significantly more time to capture, record and 
analyse the data.4,7,8 Smartphone penetration in Australia was reported at 65% in 
2013, making it a suitable market for the use of such technology.8 In the same 
survey, smartphone use is reportedly less common in other countries such as the 
United Kingdom (62%) and the United States (56%), however overall there is 
increasing smartphone penetration globally, and in future the use of this technology 
has applications any time a new vaccine is introduced.9 
 
The information obtained can be used to reassure HCP regarding the reactogenicity 
of the vaccine, and potentially used to improve uptake among HCP. Future studies 
should investigate communication strategies for informing HCP about the safety of 
IIV3. Considering the potential to prevent disease in HCP, their families and their 
patients, opportunities to disseminate safety data to HCP in real time should be 
further explored. 
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